Avastin Project
The Avastin project was launched in 2005 as a clinical registry of patients with advanced colorectal carcinoma, who have been treated with Avastin - a biological agent which specifically inhibits angiogenesis in the tumour tissue. This drug registry aims to monitor the total number of patients treated with Avastin and to collect epidemiological and clinical data of patients in order to assess the safety and effectiveness of treatment with this biological product. Thanks to the cooperation of all involved centres, data on more than 500 patients have been collected until the end of 2007, which is a clinically significant dataset from the population point of view. Moreover, Avastin has been also used in the anticancer therapy of breast and lung carcinoma since 2008 (and in therapy of renal cell carcinoma since 2010), thus enabling the epidemiological characteristics of patients, analysis of treatment response, modelling the influence of risk factors on patients' survival, as well as the detailed analysis of reported adverse effects within four different diagnoses.


The Avastin project will not only contribute to the description and monitoring of treatment results in patients with metastatic colorectal carcinoma, breast carcinoma and/or lung carcinoma; with regard to the high costs of biological therapy, it will also provide data for cost-effectiveness assessment, which could be later used to estimate costs of anticancer therapy, for example. Here are main objectives of the Avastin project:

Primary objectives of the project:

  • Monitoring the total number of patients treated with Avastin in the Czech Republic.
  • Assessing the treatment safety of Avastin.
  • Assessing the treatment effectiveness of Avastin.

Secondary objectives of the project:

  • Analysis of patients' survival in relation to monitored clinical factors.
  • Analysis of data from patients treated with Avastin in relation to reference population data of the Czech Republic.

The parametric structure of the registry contains clinical data concerning the diagnosis and extent of disease, as well as data on patient's treatment. The latter are further divided into records related to periods before and after start of treatment by Avastin. Separate forms are used to record potential adverse drug reactions which could occur during the treatment.